Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PALISADE BIO, INC.

(PALI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Palisade Bio : Maxim Starts Palisade Bio at Buy With $7 Price Target

08/31/2021 | 07:42am EST


ę MT Newswires 2021
All news about PALISADE BIO, INC.
12/08Palisade Bio Wins US Patent on Protease Inhibitor for Treating Adhesions, Bowel Obstruc..
MT
12/08Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Ad..
AQ
11/30Palisade Bio to be Granted European Patent for Lead Drug Candidate LB1148 in December T..
MT
11/30Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug C..
AQ
11/23Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Inclu..
AQ
11/23PALISADE BIO, INC. : Change in Directors or Principal Officers, Submission of Matters to a..
AQ
11/15Palisade Bio Reports Third Quarter Financial Results
AQ
11/12PALISADE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
11/12Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
10/28PALISADE BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
More news
Analyst Recommendations on PALISADE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -29,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,63x
Yield 2021 -
Capitalization 27,1 M 27,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 10
Free-Float 81,8%
Chart PALISADE BIO, INC.
Duration : Period :
Palisade Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALISADE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,00 $
Average target price 7,00 $
Spread / Average Target 250%
EPS Revisions
Managers and Directors
Thomas M. Hallam Chief Executive Officer & Director
J. D. Finley Chief Financial Officer
Ryker Willie Finance Director & Controller
James R. Neal Chairman
John Rodenrys Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
PALISADE BIO, INC.-62.12%27
MODERNA, INC.171.27%114 904
LONZA GROUP AG30.52%59 816
IQVIA HOLDINGS INC.51.92%51 999
SEAGEN INC.-14.61%27 346
CELLTRION, INC.-42.20%24 169